Clinical Trials & Studies

Lower Back and Sciatica Pain

BSC Envision

Study Title

RELIEF Study – ENVISION Cohort

Purpose

The objective of the study is to characterize the relationship between select objective metrics and clinical outcomes in chronic pain patients treated with Boston Scientific commercially approved neurostimulation systems and may use observed relationships to make recommendations.

Basic Eligibility Criteria

  • 18 years of age and older
  • Planning to receive or has received a commercially approved Boston Scientific neurostimulation system for pain per local directions for use.

Study Site Locations

Springhill 2 and Ayers

Contact

Regina Knudsen, 352-273-6786, rknudsen@anest.ufl.edu


BSC RAPID RFA

Study Title

Radiofrequency (RF) Ablation Prospective Outcomes Study

Purpose

To compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems in the treatment of patients diagnosed with pain

Basic Eligibility Criteria

  • 18 years of age or older
  • Being treated with Boston Radio Frequency Ablation for pain

Study Site Location

Springhill 2 and Ayers

Contact

Amanda Slater, 352-273-8952, aslater@anest.ufl.edu


SI Stem Cell Injection

Study Title

A phase 1, open label dose-ranging study to assess the safety, tolerability, preliminary efficacy, and dose effect of CFL001 cord blood product in patients with symptomatic sacroiliac joint syndrome.

Purpose

The overall objective is to evaluate the safety and potential efficacy effect of specific type of umbilical cord blood product (CFL001).

Basic Eligibility Criteria

  • 18 to 90 years old
  • SI joint syndrome
  • Have tried and failed other conservative pain therapies (i.e. Tylenol, NSAIDs, Tramadol, etc.)

Study Site Location(s)

Springhill 2 and Ayers

Contact

Amy Gunnett, RN, CCRC, 352-273-8911, agunnett@anest.ufl.edu

Knee Pain

SKOAP

Study Title

A Sequenced Strategy for Improving Outcomes in People with Knee Osteoarthritis Pain (SKOAP)

Purpose

  • To determine the extent to which duloxetine and the combined effects of painTrainer and duloxetine improve pain and function in participants with KOA and/or
  • Among those interested in additional treatment, including those following conservative treatment and those inappropriate for conservative care, determine whether nonsurgical procedural interventions improve pain and function.

Basic Eligibility Criteria

  • 18 years of age to 80 years of age
  • Diagnosis of knee osteoarthritis
  • Have insurance or willing to pay out of pocket
  • Have access to reliable internet

Study Site Locations

Springhill 2 and Ayers

Contact

Amanda Slater, 352-273-8952, aslater@anest.ufl.edu

Study Website

Learn more at skoapstudy.org


EN20-01 Centrexion

Study Title

EN20-01: A 24-Week study to evaluate the safety and efficiency of CNTX-6970 in subjects with moderate to severe knee osteoarthritis pain.

Purpose

To evaluate the safety and effectiveness of the drug CNTX-6970 on the treatment of knee osteoarthritis.

Basic Eligibility Criteria

  • 40 years of age to 80 years of age
  • Osteoarthritis of the knee
  • No current use of pain medication, other than Tylenol

Study Site Location

Springhill 2

Contact

Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu

Pelvic Pain

Abbott REALITY (pelvic pain only)

Study Title

Long-Term Real-World Outcomes Study on Patients Implanted with a Neurostimulator

Purpose

To capture long-term, real-world, safety and effectiveness data on Abbott’s market released neurostimulator systems.

Basic Eligibility Criteria

  • 18 years of age and older
  • Get a SCS or DRG implant

Study Site Locations

Springhill 2 and Ayers

Contact

Amanda Slater, 352-273-8952, aslater@anest.ufl.edu

Diabetic Neuropathy

EN21-01 Diabetic Peripheral Neuropathy

Contact

Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu


EN21-02 Diabetic Peripheral Neuropathy

Contact

Brandi Lattinville, 352-294-8346, blattinville@anest.ufl.edu

Cancer Pain

Sorrento

Study Title

A multicenter phase 2 study to assess the safety and efficacy of epidural resiniferatoxin for the treatment of intractable pain associated with advanced cancer.

Purpose

  • To assess the safety of epidural RTX compared to the control groups
    • Short-term treatment-emergent AEs (TEAEs) during the 6- and 24-hours post RTX administration
    • Long-term TEAEs, particularly AEs of special interest (AESIs)
      • Neurologic disorders in the area below the injection target
      • Bladder incontinence

Basic Eligibility Criteria

  • 18 years of age or older
  • Have advanced or metastatic cancer
  • Have pain that is “intractable” in that it has not responded to standard therapies

Study Site Location(s)

Springhill 2 and Florida Surgical Center

Contact

Amy Gunnett, RN, CCRC, 352-273-8911, agunnett@anest.ufl.edu